Answering reviewers

Reviewer’s code: 05607090

SPECIFIC COMMENTS TO AUTHORS
The main therapies for primary liver cancer include liver transplantation, surgical resection, local ablation therapy, TACE and targeted therapy. The onset of this disease is insidious and it develops very fast. When primary liver cancer is confirmed in a patient, generally it means a high degree of malignancy and the patient has lost the best opportunity of surgical resection. Liposoluble chemotherapy agents dissolved in lipiodol can stay longer in liver tumor, which may strengthen the anti-tumor efficacy of chemotherapy agents. In this study, the authors discussed the efficacy of TACE with pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer and PFS, OS, clinical response rate, disease control rate, liver and kidney function and adverse reactions. The manuscript is overall well written. The aim is clear, and the results are well displayed. Some minor editing is required.

Answer: Thank you very much for your comments. The manuscript was edited according to the journal’s guidelines carefully.

Reviewer’s code: 05769444

SPECIFIC COMMENTS TO AUTHORS
This is an interesting study about the efficacy and safety of TACE for primary liver cancer. The study is well performed. The results are very well discussed. The references should be edited and updated.

Answer: Thank you very much. The references have been edited and updated accordingly. The full manuscript was also edited and proofed carefully.